A Call for More Inclusive,Patient-Centered Nomenclature for Antipsychotics in the Treatment of Autism Spectrum Disorder

Abstract

Risperidone and aripiprazole are US Food and Drug Administration (FDA)–approved to treat irritability and aggression in autism spectrum disorder. This is a time to reflect on whether the terminology of these medications is respectful to this patient population. Misleading terminology can give rise to uncertainty and delay in treatment. Based on past examples of evolving medication nomenclature, we advocate for a change in the language used to describe these medications to improve clarity surrounding treatment and support inclusive and positive care experiences.